NME "Approvables" Outnumber Approvals Six To Two In October
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
An "approvable" action was three times more likely than approval for the new molecular entities with user fee goals in October, according to an analysis by Pharmaceutical Approvals Monthly.